IgGs from patients with amyotrophic lateral sclerosis and diabetes target Ca<sub>V</sub>α<sub>2</sub>δ1 subunits impairing islet cell function and survival.

Shi, Yue; Park, Kyoung Sun; Kim, Seung Hyun; Yu, Jia; Zhao, Kaixuan; Yu, Lina; Oh, Ki Wook; Lee, Kayoung et al. · Proc Natl Acad Sci U S A · 2019

basic_science · Level V

Where this comes from

Abstract

Patients with amyotrophic lateral sclerosis (ALS) often show hallmarks of type 2 diabetes mellitus (T2DM). However, the causal link between ALS and T2DM has remained a mystery. We now demonstrate that 60% of ALS patients with T2DM (ALS-T2DM) have sera that exaggerated K<sup>+</sup>-induced increases in cytosolic free Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) in mouse islet cells. The effect was attributed to the presence of pathogenic immunoglobulin Gs (IgGs) in ALS-T2DM sera. The pathogenic IgGs immunocaptured the voltage-dependent Ca<sup>2+</sup> (Ca<sub>V</sub>) channel subunit Ca<sub>V</sub>α<sub>2</sub>δ1 in the plasma membrane enhancing Ca<sub>V</sub>1 channel-mediated Ca<sup>2+</sup> influx and [Ca<sup>2+</sup>]<sub>i</sub>, resulting in impaired mitochondrial function. Consequently, impairments in [Ca<sup>2+</sup>]<sub>i</sub> dynamics, insulin secretion, and cell viability occurred. These data reveal that patients with ALS-T2DM carry cytotoxic ALS-T2DM-IgG autoantibodies that serve as a causal link between ALS and T2DM by immunoattacking Ca<sub>V</sub>α<sub>2</sub>δ1 subunits. Our findings may lay the foundation for a pharmacological treatment strategy for patients suffering from a combination of these diseases.